RxDoctor Payments Data

Mary Lupo, MD

Procedural Dermatology · New Orleans, LANPI 1649273152

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (55.8%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Solta Medical, A Division Of Bausch Health US, LLC at 38.4% of the total. Reporting peaked in 2019 at $24,890 and has fallen 91.9% since, to $2,027 in 2025.

$91,013in general payments, 2019–2025

Across 338 payments — averaging $269.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Solta Medical, A Division Of Bausch Health US, LLC$35K
  • Lumenis, Inc$17K
  • Merz North America, Inc.$12K
  • Ortho Dermatologics, A Division Of Bausch Health US, LLC$12K
  • AbbVie$9K
  • Galderma Laboratories, L.p.$3K
  • plus $4K from 24 others
$134,873in research payments, 2019–2025

Across 39 payments — averaging $3458.29 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merz North America, Inc.$86K
  • AbbVie$42K
  • Endo Pharmaceuticals Inc.$3K
  • Amgen$2K
  • Bausch Health US, LLC$2K

What the payments were for

  • Consulting fees$50,79056%
  • Speaking & faculty fees$19,36821%
  • Grants$200%
  • Travel & lodging$10,64012%
  • Food & beverage$10,16911%
  • Education$250%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few procedural dermatology providers in Louisianato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,700
Medicare patients
29
Services billed
72

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ValacyclovirValacyclovir Hcl50$730

Paid to pharmacies, not to this prescriber.

Other procedural dermatology in New Orleans

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →